S. Lu

发表

First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study.

B. Han, G. Jiang, H. Pan, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update

D. Carbone, E. Felip, T. John, 2021, ESMO open.

Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial

R. Greil, O. Popovych, C. Gridelli, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

An unblinded, randomised phase II study of platinum-based chemotherapy with vitamin B12 and folic acid supplementation in the treatment of lung cancer with plasma homocysteine blood levels as a biomarker of severe neutropenic toxicity

K. Yu, M. O'Brien, S. Lu, 2014, BMJ Open Respiratory Research.

Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer)

T. Mok, Y. Ichinose, M. Maemondo, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

1222OA RANDOMIZED, OPEN-LABEL, PHASE III TRIAL OF AFATINIB (A) VS ERLOTINIB (E) AS SECOND-LINE TREATMENT OF PATIENTS (PTS) WITH ADVANCED SQUAMOUS CELL CARCINOMA (SCC) OF THE LUNG FOLLOWING FIRST-LINE PLATINUM-BASED CHEMOTHERAPY: LUX-LUNG 8 (LL8).

K. Syrigos, E. Felip, J. Soria, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS.

T. Mitsudomi, S. Peters, D. Planchard, 2019, Annals of Oncology.

Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial.

K. O'Byrne, T. Mok, E. Tan, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Updated efficacy and quality-of-life (QoL) analyses in OPTIMAL, a phase III, randomized, open-label study of first-line erlotinib versus gemcitabine/carboplatin in patients with EGFR-activating mutation-positive (EGFR Act Mut+) advanced non-small cell lung cancer (NSCLC).

Y. Wu, C. Zhou, X. Liu, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term clinical and molecular remissions in patients with follicular lymphoma following high-dose therapy and autologous stem cell transplantation

Y. Luo, Y. Wu, C. Zhou, 2013 .

Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802).

Y. Wu, Y. Luo, Q. Xiu, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS

T. Mitsudomi, S. Peters, D. Planchard, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Lymph node involvement influenced by lung adenocarcinoma subtypes in tumor size ≤3 cm disease: A study of 2268 cases.

S. Lu, L. Shen, Y. Yu, 2016, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

1265PPATIENT-REPORTED OUTCOMES (PROS) IN PATIENTS (PTS) WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) RECEIVING AFATINIB (A) MONOTHERAPY FOLLOWED BY A + PACLITAXEL (A + P) VS INVESTIGATOR'S CHOICE OF SINGLE-AGENT CHEMOTHERAPY (IC): LUX-LUNG 5 (LL5).

F. de Marinis, D. Planchard, M. Schuler, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial.

Ying Cheng, Yi-long Wu, Jin-Ji Yang, 2017, The Lancet. Respiratory medicine.

Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial

K. O'Byrne, T. Mok, E. Tan, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials.

Y Huang, L. Sequist, K. O'Byrne, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Adenovirus Mediated Knockdown and Bone Morphogenetic Protein 2 Inhibits Human Lung Cancer Growth and Invasion In Vitro and in Vivo

S. Lu, X. Niu, Naiwang Tang, 2012, International journal of immunopathology and pharmacology.

Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer).

T. Mok, Y. Ichinose, M. Maemondo, 2017 .

Whole brain radiation therapy followed by intensity-modulated boosting treatment combined with concomitant temozolomide for brain metastases from non-small-cell lung cancer

C. Leng, S. Lu, Shiyong Lu, 2014, Clinical and Translational Oncology.

A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC)

M. Aapro, A. Dechaphunkul, S. Lu, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803).

Yi-long Wu, Y. Wu, C. Zhou, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

A meta-analysis of STAT3 and phospho-STAT3 expression and survival of patients with non-small-cell lung cancer.

S. Lu, Y. Xu, S. Lu, 2014, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

132P Randomized phase III study of tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous non-small cell lung cancer (sq-NSCLC): RATIONALE-307 updated analysis

K. Yang, S. Lu, Y. Song, 2022, Immuno-Oncology and Technology.

VP9-2021: ORIENT-31: Phase III study of sintilimab with or without IBI305 plus chemotherapy in patients with EGFR mutated nonsquamous NSCLC who progressed after EGFR-TKI therapy

S. Lu, Y. Cheng, B. Li, 2021, Annals of Oncology.

A phase II study (CTONG0803) of erlotinib as second-line treatment in advanced non-small cell lung cancer (NSCLC) patients (pts) with asymptomatic brain metastases (BM) after first-line chemotherapy (CT).

Y. Wu, C. Zhou, S. Lu, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy of single dose NEPA, a fixed combination of netupitant and palonosetron, versus a 3-day regimen of aprepitant/granisetron (APR/GRAN) for prevention of nausea in patients receiving high dose cisplatin.

A. Dechaphunkul, S. Olivari, S. Lu, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.